Zoetis Inc. (ZTS)
Zoetis (ZTS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.56 per share a year ago.
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Here's Why Zoetis (ZTS) Fell More Than Broader Market
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Laps the Stock Market: Here's Why
In the most recent trading session, Zoetis (ZTS) closed at $151.19, indicating a +2.59% shift from the previous trading day.
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
Zoetis Inc. is the dominant animal health company, growing market share, revenue, and margins, now trading at a multi-year low valuation. Fundamentals remain strong: rising EPS, aggressive buybacks, and a shareholder yield of 3.2% with robust secular tailwinds supporting long-term growth. Key franchises (Simparica, Apoquel, Librela) are expanding, protected by patents, into the 2030s-2040s, with further growth potential from under-penetrated markets.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis: Growth To Continue Thanks To Companion Animals
Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's leadership, scale, and innovation position it well against new competitors. Financials show steady revenue, profit, and dividend growth, with management raising full-year guidance and focusing on expanding key product lines.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
